Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Protein
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
L0423Z5LDW
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
CYTOCHROME P450 2C8
Common Name
English  
HUMAN CYTOCHROME P450 2C8
Common Name
English  
CYTOCHROME P 450 2C8
Common Name
English  
CYP2C8 (HUMAN)
Common Name
English  
CYP2C8
Common Name
English  
CYP-2C8
Common Name
English  
Code System Code Type Description Access References
CAS
330207-13-1
Created by admin on Wed Aug 04 21:56:26 EDT 2021 , Edited by admin on Wed Aug 04 21:56:26 EDT 2021
PRIMARY
FDA UNII
L0423Z5LDW
Created by admin on Wed Aug 04 21:56:26 EDT 2021 , Edited by admin on Wed Aug 04 21:56:26 EDT 2021
PRIMARY
UNIPROT
P10632
Created by admin on Wed Aug 04 21:56:26 EDT 2021 , Edited by admin on Wed Aug 04 21:56:26 EDT 2021
PRIMARY
Related Record Type Details Access References
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Human hepatic CYP2C8 activities after incubation with different pesticides showed that CYP2C8 activities were inhibited extensively by malathion (100,90%).
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:41 EDT 2021 , Edited by admin on Wed Aug 04 21:56:41 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:56:37 EDT 2021 , Edited by admin on Wed Aug 04 21:56:37 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:41 EDT 2021 , Edited by admin on Wed Aug 04 21:56:41 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:28 EDT 2021 , Edited by admin on Wed Aug 04 21:56:28 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:56:40 EDT 2021 , Edited by admin on Wed Aug 04 21:56:40 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:26 EDT 2021 , Edited by admin on Wed Aug 04 21:56:26 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
LOW
Ki
Created by admin on Wed Aug 04 21:56:37 EDT 2021 , Edited by admin on Wed Aug 04 21:56:37 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:42 EDT 2021 , Edited by admin on Wed Aug 04 21:56:42 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:40 EDT 2021 , Edited by admin on Wed Aug 04 21:56:40 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:26 EDT 2021 , Edited by admin on Wed Aug 04 21:56:26 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:43 EDT 2021 , Edited by admin on Wed Aug 04 21:56:43 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:42 EDT 2021 , Edited by admin on Wed Aug 04 21:56:42 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:37 EDT 2021 , Edited by admin on Wed Aug 04 21:56:37 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:29 EDT 2021 , Edited by admin on Wed Aug 04 21:56:29 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:45 EDT 2021 , Edited by admin on Wed Aug 04 21:56:45 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:27 EDT 2021 , Edited by admin on Wed Aug 04 21:56:27 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:37 EDT 2021 , Edited by admin on Wed Aug 04 21:56:37 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:40 EDT 2021 , Edited by admin on Wed Aug 04 21:56:40 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:40 EDT 2021 , Edited by admin on Wed Aug 04 21:56:40 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MODERATE
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:41 EDT 2021 , Edited by admin on Wed Aug 04 21:56:41 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:41 EDT 2021 , Edited by admin on Wed Aug 04 21:56:41 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Human hepatic CYP2C8 activities after incubation with different pesticides showed that CYP2C8 activities were inhibited extensively by phenthoate (100,90%).
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:40 EDT 2021 , Edited by admin on Wed Aug 04 21:56:40 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:32 EDT 2021 , Edited by admin on Wed Aug 04 21:56:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 21:56:26 EDT 2021 , Edited by admin on Wed Aug 04 21:56:26 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
CYP2C8
IC50
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:32 EDT 2021 , Edited by admin on Wed Aug 04 21:56:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Ki
Created by admin on Wed Aug 04 21:56:30 EDT 2021 , Edited by admin on Wed Aug 04 21:56:30 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:40 EDT 2021 , Edited by admin on Wed Aug 04 21:56:40 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Glasdegib is metabolized primarily by the CYP3A4 pathway, with minor contributions by CYP2C8 and UGT1A9
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
IC50
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:56:36 EDT 2021 , Edited by admin on Wed Aug 04 21:56:36 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
clascoterone cream, 1%, has no clinically meaningful effect on the PK of drugs metabolized by CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A4.
IC50
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:37 EDT 2021 , Edited by admin on Wed Aug 04 21:56:37 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:41 EDT 2021 , Edited by admin on Wed Aug 04 21:56:41 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:56:37 EDT 2021 , Edited by admin on Wed Aug 04 21:56:37 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:34 EDT 2021 , Edited by admin on Wed Aug 04 21:56:34 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK
IC50
Created by admin on Wed Aug 04 21:56:41 EDT 2021 , Edited by admin on Wed Aug 04 21:56:41 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:41 EDT 2021 , Edited by admin on Wed Aug 04 21:56:41 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:29 EDT 2021 , Edited by admin on Wed Aug 04 21:56:29 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:36 EDT 2021 , Edited by admin on Wed Aug 04 21:56:36 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:27 EDT 2021 , Edited by admin on Wed Aug 04 21:56:27 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:36 EDT 2021 , Edited by admin on Wed Aug 04 21:56:36 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:43 EDT 2021 , Edited by admin on Wed Aug 04 21:56:43 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:34 EDT 2021 , Edited by admin on Wed Aug 04 21:56:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:37 EDT 2021 , Edited by admin on Wed Aug 04 21:56:37 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
In vitro studies with human hepatic microsomes showed that abiraterone has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:41 EDT 2021 , Edited by admin on Wed Aug 04 21:56:41 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:43 EDT 2021 , Edited by admin on Wed Aug 04 21:56:43 EDT 2021
TISSUE EXPRESSION -> PARENT
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:40 EDT 2021 , Edited by admin on Wed Aug 04 21:56:40 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IN VITRO
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
REVERSIBLE
Created by admin on Wed Aug 04 21:56:37 EDT 2021 , Edited by admin on Wed Aug 04 21:56:37 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (< 1%).
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:42 EDT 2021 , Edited by admin on Wed Aug 04 21:56:42 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:39 EDT 2021 , Edited by admin on Wed Aug 04 21:56:39 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:31 EDT 2021 , Edited by admin on Wed Aug 04 21:56:31 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:56:42 EDT 2021 , Edited by admin on Wed Aug 04 21:56:42 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
In vivo, the sum of enzalutamide and M2 exposure was increased by 2.2-fold and 1.3-fold when it was co-administered with gemfibrozil (strong CYP2C8 inhibitor) or itraconazole (strong CYP3A4 inhibitor), respectively. If the co-administration of enzalutamide with a strong CYP2C8 inhibitor cannot be avoided, the daily enzalutamide dose should be reduced to 80 mg.
Created by admin on Wed Aug 04 21:56:40 EDT 2021 , Edited by admin on Wed Aug 04 21:56:40 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:40 EDT 2021 , Edited by admin on Wed Aug 04 21:56:40 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:34 EDT 2021 , Edited by admin on Wed Aug 04 21:56:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
WEAK
In vitro data suggests that avatrombopag weakly induces CYP2C8 and CYP2C9
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
METABOLIC ENZYME -> INHIBITOR
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:32 EDT 2021 , Edited by admin on Wed Aug 04 21:56:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
inhibitions between 59 and 84% were observed with profenofos
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:33 EDT 2021 , Edited by admin on Wed Aug 04 21:56:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:41 EDT 2021 , Edited by admin on Wed Aug 04 21:56:41 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:37 EDT 2021 , Edited by admin on Wed Aug 04 21:56:37 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
TIME-DEPENDENT INHIBITION
Pretomanid is a weak time-dependent inhibitor of CYP2C8 and CYP2C19.
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
INDUCER -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:56:38 EDT 2021 , Edited by admin on Wed Aug 04 21:56:38 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:37 EDT 2021 , Edited by admin on Wed Aug 04 21:56:37 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:56:26 EDT 2021 , Edited by admin on Wed Aug 04 21:56:26 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
inhibitions between 59 and 84% were observed with fenitrothion
Created by admin on Wed Aug 04 21:56:44 EDT 2021 , Edited by admin on Wed Aug 04 21:56:44 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 21:56:35 EDT 2021 , Edited by admin on Wed Aug 04 21:56:35 EDT 2021
Structural Modifications
Modification Type Location Site Location Type Residue Modified Extent Modification Name Modification ID Access
Heme binding [1_435] CYS HEME-CYSTEINE (OXIDIZED) G0HAF1JK3T
Name Property Type Amount Referenced Substance Defining Parameters Access References
Molecular Formula CHEMICAL
0
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED) CHEMICAL
0
Created Wed Aug 04 21:56:09 EDT 2021
Created By admin
Last Edited Wed Aug 04 21:56:09 EDT 2021
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File Access
1 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213433Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
2 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
3 Ghosal, Anima, et al. "Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar)." Drug metabolism and disposition 34.4 (2006): 628-635. JA PUBLIC_DOMAIN_RELEASE
4 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000ClinpharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
5 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
6 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
7 Hu, Yiding, and David Kupfer. "Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite." Drug metabolism and disposition 30.9 (2002): 1035-1042. JA PUBLIC_DOMAIN_RELEASE
8 In Vitro Characterization of Sarizotan Metabolism: Hepatic Clearance, Identification and Characterization of Metabolites, Drug-Metabolizing Enzyme Identification, and Evaluation of Cytochrome P450 Inhibition Dieter Gallemann, Elmar Wimmer, Constance C. Höfer, Achim Freisleben, Markus Fluck, Bernhard Ladstetter and Hugues Dolgos Drug Metabolism and Disposition June 2010, 38 (6) 905-916; DOI: https://doi.org/10.1124/dmd.109.029835 JA PUBLIC_DOMAIN_RELEASE
9 Drug Metabolism and Disposition December 2002, 30 (12) 1352-1356; DOI: JA
10 Itkonen, Matti K., et al. "Clopidogrel and gemfibrozil strongly inhibit the CYP2C8-dependent formation of 3-hydroxydesloratadine and increase desloratadine exposure in humans." Drug Metabolism and Disposition 47.4 (2019): 377-385. JA PUBLIC_DOMAIN_RELEASE
11 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021882_s000_Exjade_BioPharmr.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
12 Prakash, Chandra, et al. "CYP2C8-and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance." Drug metabolism and disposition 36.10 (2008): 2093-2103. JA PUBLIC_DOMAIN_RELEASE
13 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202992Orig1s000ClinpharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
14 SRS import [L0423Z5LDW] SRS NOMEN Fri Apr 28 15:16:48 EDT 2017
15 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
16 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
17 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
18 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
19 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
20 Generated from relationship on:'CARBAMAZEPINE' SYSTEM
21 dump-public-2021-07-22_UPDATED.gsrs BATCH_IMPORT Wed Aug 04 21:56:06 EDT 2021
22 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW
23 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
24 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
25 DOI: 10.1124/DMD.30.6.631\\nDMD JUNE 1, 2002 VOL. 30 NO. 6 631-635 JOURNAL ARTICLE NOMEN
26 Kazmi, Faraz, et al. "A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement." Drug Metabolism and Disposition 43.4 (2015): 523-533. JA PUBLIC_DOMAIN_RELEASE
27 http://dmd.aspetjournals.org/content/39/4/693 WEBSITE NOMEN
28 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
29 Abass, Khaled, Miia Turpeinen, and Olavi Pelkonen. "An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes." Journal of Environmental Science and Health, Part B 44.6 (2009): 553-563. JA PUBLIC_DOMAIN_RELEASE
30 Jan?ová, Petra, et al. "Silybin is metabolized by cytochrome P450 2C8 in vitro." Drug metabolism and disposition 35.11 (2007): 2035-2039. JA PUBLIC_DOMAIN_RELEASE
31 Becquemont, Laurent, et al. "Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism." Drug metabolism and disposition 27.9 (1999): 1068-1073. JA PUBLIC_DOMAIN_RELEASE
32 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
33 CYP-Mediated Sulfoximine Deimination of AZD6738 Barry C. Jones, Roshini Markandu, Chungang Gu and Graeme Scarfe Drug Metabolism and Disposition November 2017, 45 (11) 1133-1138; DOI: https://doi.org/10.1124/dmd.117.077776 JA PUBLIC_DOMAIN_RELEASE
34 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
35 Ventura, Veronica, et al. "In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification." Drug metabolism and disposition 39.7 (2011): 1235-1246. JA PUBLIC_DOMAIN_RELEASE
36 Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development Jim Zheng, Yan Xin, Jingyu Zhang, Raju Subramanian, Bernard P. Murray, J. Andrew Whitney, Matthew R. Warr, John Ling, Lisa Moorehead, Ellen Kwan, Jeffrey Hemenway, Bill J. Smith and Jeffrey A. Silverman Drug Metabolism and Disposition March 2018, 46 (3) 237-247; DOI: https://doi.org/10.1124/dmd.117.078899 JA PUBLIC_DOMAIN_RELEASE
37 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
38 DRUG METAB DISPOS 41:50?59, JANUARY 2013 JOURNAL ARTICLE NOMEN
39 DRUG METABOLISM HANDBOOK, ED. A.F. NASSER, 2009, PG:371 BOOK NOMEN
40 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
41 https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
42 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
43 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
44 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
45 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-264_Apokyn_BioPharmr_P1.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
46 Abass, Khaled, Miia Turpeinen, and Olavi Pelkonen. "An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes." Journal of Environmental Science and Health, Part B 44.6 (2009): 553-563. JA PUBLIC_DOMAIN_RELEASE
47 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
48 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
49 FDA_SRS SRS NOMEN
50 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210656Orig1s000SumR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
51 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
52 Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites Steven Lacy, Bih Hsu, Dale Miles, Dana Aftab, Ronghua Wang and Linh Nguyen Drug Metabolism and Disposition August 2015, 43 (8) 1190-1207; DOI: https://doi.org/10.1124/dmd.115.063610 JA PUBLIC_DOMAIN_RELEASE
53 Projean, Denis, et al. "In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation." Drug Metabolism and Disposition 31.6 (2003): 748-754. JA PUBLIC_DOMAIN_RELEASE
54 In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase Wolfgang Albrecht, Anke Unger, Andreas K. Nussler and Stefan Laufer Drug Metabolism and Disposition May 2008, 36 (5) 894-903; DOI: https://doi.org/10.1124/dmd.108.020347 JA PUBLIC_DOMAIN_RELEASE
55 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
56 UNIPROT UNIPROT NOMEN
57 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
58 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206619Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
59 Generated from relationship on:'OXYMETAZOLINE' SYSTEM
60 Abass, Khaled, Miia Turpeinen, and Olavi Pelkonen. "An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes." Journal of Environmental Science and Health, Part B 44.6 (2009): 553-563. JA PUBLIC_DOMAIN_RELEASE
61 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836Orig1s000_205837Orig1s000_205838Orig1s000OtherR.pdf NDA PUBLIC REVIEW NOMEN
62 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
63 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
64 https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
65 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
66 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
67 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
68 Walles, Markus, et al. "Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects." Drug Metabolism and Disposition 41.9 (2013): 1626-1641. JA PUBLIC_DOMAIN_RELEASE
69 Chang, Yan, David E. Moody, and Elinore F. McCance-Katz. "Novel metabolites of buprenorphine detected in human liver microsomes and human urine." Drug Metabolism and Disposition 34.3 (2006): 440-448. JA PUBLIC_DOMAIN_RELEASE
70 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, NOV. 2003, P. 3464?3469 JOURNAL ARTICLE NOMEN
71 STN SRS NOMEN
72 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208627Orig1s000SumR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
73 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
74 Gerisch, Michael, et al. "Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro." Drug Metabolism and Disposition 46.11 (2018): 1546-1555. JA PUBLIC_DOMAIN_RELEASE
75 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513 DAILYMED
76 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
77 https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
78 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
79 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213433Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
80 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
81 Attar, Mayssa, et al. "Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans." Drug metabolism and disposition 31.4 (2003): 476-481. JA PUBLIC_DOMAIN_RELEASE
82 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000_ClinPharmR_P1.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
83 Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites Steven Lacy, Bih Hsu, Dale Miles, Dana Aftab, Ronghua Wang and Linh Nguyen Drug Metabolism and Disposition August 2015, 43 (8) 1190-1207; DOI: https://doi.org/10.1124/dmd.115.063610 JA PUBLIC_DOMAIN_RELEASE
84 Zheng, Nan, et al. "In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes." Drug metabolism and disposition 39.4 (2011): 627-635. JA PUBLIC_DOMAIN_RELEASE
85 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
86 Abass, Khaled, Miia Turpeinen, and Olavi Pelkonen. "An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes." Journal of Environmental Science and Health, Part B 44.6 (2009): 553-563. JA PUBLIC_DOMAIN_RELEASE
87 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
88 Dunkoksung, Wilasinee, et al. "Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes." Drug Metabolism and Disposition 47.10 (2019): 1040-1049. JA PUBLIC_DOMAIN_RELEASE
89 Ballard, Jeanine E., Thomayant Prueksaritanont, and Cuyue Tang. "Hepatic metabolism of MK-0457, a potent aurora kinase inhibitor: interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase." Drug metabolism and disposition 35.9 (2007): 1447-1451. JA PUBLIC_DOMAIN_RELEASE
90 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209195Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
91 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
92 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210496Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
93 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
94 Uchiyama, Minoru, et al. "In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor ? agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes." Drug metabolism and disposition 39.7 (2011): 1311-1319. JA PUBLIC_DOMAIN_RELEASE
95 Kitamura, Ryuichi, et al. "Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1, 2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68)." Drug metabolism and disposition 36.6 (2008): 1003-1009. JA PUBLIC_DOMAIN_RELEASE
96 UNIPROT SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
97 Nucleic Acids Research, 2010, Vol. 38, Database issue D237–D243 doi:10.1093/nar/gkp970 JA
98 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205422Orig1Orig2s000PharmR.pdf NDA PUBLIC REVIEW NOMEN
99 Jan?ová, Petra, et al. "Silybin is metabolized by cytochrome P450 2C8 in vitro." Drug metabolism and disposition 35.11 (2007): 2035-2039. JA PUBLIC_DOMAIN_RELEASE
100 Generated from relationship on:'IMATINIB' SYSTEM
101 Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans Caroline A. Lee, Chun Yang, Vishal Shah, Zancong Shen, David M. Wilson, Traci M. Ostertag, Jean-Luc Girardet, Jesse Hall and Michael Gillen Drug Metabolism and Disposition May 2018, 46 (5) 532-541; DOI: https://doi.org/10.1124/dmd.117.078220 JA PUBLIC_DOMAIN_RELEASE
102 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
103 Kumar, Gondi N., et al. "Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001)." Drug metabolism and disposition 25.1 (1997): 110-115. JA PUBLIC_DOMAIN_RELEASE
104 Generated from relationship on:'GEMFIBROZIL' SYSTEM
105 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213189s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
106 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204819Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
107 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210868Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
108 Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites Steven Lacy, Bih Hsu, Dale Miles, Dana Aftab, Ronghua Wang and Linh Nguyen Drug Metabolism and Disposition August 2015, 43 (8) 1190-1207; DOI: https://doi.org/10.1124/dmd.115.063610 JA PUBLIC_DOMAIN_RELEASE
109 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW
110 Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor Faraz Kazmi, Phyllis Yerino, Joanna E. Barbara and Andrew Parkinson Drug Metabolism and Disposition September 2015, 43 (9) 1294-1302; DOI: https://doi.org/10.1124/dmd.115.065011 JA PUBLIC_DOMAIN_RELEASE
111 SRS CODE IMPORT SRS NOMEN Fri Apr 28 15:16:48 EDT 2017
112 Nishihara, Mitsuhiro, et al. "An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide." Drug Metabolism and Disposition 40.2 (2012): 249-258. JA PUBLIC_DOMAIN_RELEASE
113 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
114 Gorman, Gregory S., et al. "In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid." Drug metabolism and disposition 35.7 (2007): 1157-1164. JA PUBLIC_DOMAIN_RELEASE
115 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
116 Generated from relationship on:'BREXPIPRAZOLE' SYSTEM
117 STN STN (SCIFINDER)
118 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
119 PHARMACOGENOMICS\\nJANUARY 2013, VOL. 14, NO. 1, PAGES 35-45 , DOI 10.2217/PGS.12.180 JOURNAL ARTICLE NOMEN
120 Wang, Bonnie, et al. "The involvement of CYP3A4 and CYP2C9 in the metabolism of 17?-ethinylestradiol." Drug metabolism and disposition 32.11 (2004): 1209-1212. JA PUBLIC_DOMAIN_RELEASE
121 Wang, Jun-Sheng, and C. Lindsay DeVane. "Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro." Drug Metabolism and Disposition 31.6 (2003): 742-747. JA PUBLIC_DOMAIN_RELEASE
122 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
123 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
124 Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites Steven Lacy, Bih Hsu, Dale Miles, Dana Aftab, Ronghua Wang and Linh Nguyen Drug Metabolism and Disposition August 2015, 43 (8) 1190-1207; DOI: https://doi.org/10.1124/dmd.115.063610 JA PUBLIC_DOMAIN_RELEASE
125 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209195Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
126 Cherstniakova, Svetlana A., et al. "Metabolism of vanoxerine, 1-[2-[bis (4-fluorophenyl) methoxy] ethyl]-4-(3-phenylpropyl) piperazine, by human cytochrome P450 enzymes." Drug metabolism and disposition 29.9 (2001): 1216-1220. JA PUBLIC_DOMAIN_RELEASE
127 Disposition and Metabolic Profiling of [14C]Cerlapirdine Using Accelerator Mass Spectrometry Susanna Tse, Louis Leung, Sangeeta Raje, Mark Seymour, Yoko Shishikura and R. Scott Obach Drug Metabolism and Disposition December 2014, 42 (12) 2023-2032; DOI: https://doi.org/10.1124/dmd.114.059675 JA PUBLIC_DOMAIN_RELEASE
128 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209299Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
129 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203108Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW
130 Generated from relationship on:'AMIODARONE' SYSTEM
131 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210923Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE